Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 59, Issue 1, 2020, Pages 153-164

  Smolen, Josef S ^a   Pedersen, Ronald ^b   Jones, Heather ^b   Mahgoub, Ehab ^b   Marshall, Lisa ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PFIZER INC   (United States)

Author keywords

etanercept; low disease activity; methotrexate; remission; rheumatoid arthritis; treatment

Indexed keywords

ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MODIFIED TOTAL SHARP SCORE; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; OPEN STUDY; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RADIOGRAPHY; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 85071102052     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kez224     Document Type: Article

References (27)

1. Drossaers-Bakker KW, de Buck M, van Zeben D et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
2. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
3. Smolen JS, Han C, van der Heijde DM. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
4. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
5. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
6. Nam JL, Takase-Minegishi K, Ramiro S et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1113-36.
7. Stevenson M, Archer R, Tosh J et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 2016;20:1-610.
8. Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.
9. Lau CS, Chia F, Harrison A et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015;18:685-713.
10. Van Herwaarden N, den Broeder AA, Jacobs W et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;doi:10.1002/14651858.CD010455.pub2.
11. Lau CS, Gibofsky A, Damjanov N et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int 2017;37:1789-98.
12. Markusse IM, Dirven L, Gerards AH et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther 2015;17:232.
13. Kuettel D, Primdahl J, Christensen R, Ornbjerg LM, Horslev-Petersen K. Impact of patient-reported flares on radiographic progression and functional impairment in patients with rheumatoid arthritis: a cohort study based on the AMBRA trial. Scand J Rheumatol 2018;47:87-94.
14. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
15. Van der Heijde D, Simon L, Smolen J et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-8.
16. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1114-21.
17. Henaux S, Ruyssen-Witrand A, Cantagrel A et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 2018;77:515-22.
18. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
19. Schoels M, Alasti F, Smolen JS, Aletaha D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther 2017;19:155.
20. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993;20:575-8.
21. van der Heijde DM, van Riel PL, van Leeuwen MA et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective followup study of 147 patients. Br J Rheumatol 1992;31:519-25.
22. van Leeuwen MA, van Rijswijk MH, van der Heijde DM et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32(Suppl 3):9-13.
23. Smolen JS, Van Der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
24. Schett G, Emery P, Tanaka Y et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75:1428-37.
25. Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
26. Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther 2018;20:8.
27. Bouman CA, van Herwaarden N, van den Hoogen FH et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study-a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis 2017;76:1716-22.